14 completed. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 2 | 1 | Completed 1 |
Follow etravirine: new trials by email Literature Review of etravirine trials Research Report on etravirine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR) - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 54 | 2020-10-28 | 2024-08-29 |
| A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants JNJ-64417184, Itraconazole, Etravirine - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 32 | 2019-12-20 | 2025-02-03 |
| Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients darunavir/cobicistat, etravirine - HIV-1 Infection | Phase 1 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 30 | 2016-06-01 | 2018-03-12 |
| DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV) BMS-663068, Darunavir (DRV), Ritonavir (RTV) - Infection, Human Immunodeficiency Virus | Phase 1 | Completed | ViiV Healthcare | 42 | 2014-02-01 | 2017-08-08 |
| Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children Etravirine (ETR) - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2013-03-14 | 2021-11-02 |
| Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine Etravirine, Darunavir/ritonavir, artemether/lumefantrine - HIV | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 33 | 2011-03-01 | 2013-06-13 |
| TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients etravirine - HIV-Infections | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 49 | 2010-03-01 | 2012-12-11 |
| DDI Study of Etravirine and GSK1265744 GSK1265744 - Healthy Subjects, Infection, Human Immunodeficiency Virus | Phase 1 | Completed | GlaxoSmithKline | 12 | 2009-07-01 | 2010-08-31 |
| Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue darunavir, Ritonavir, Etravirine - HIV/AIDS, HIV Infections | Phase 1 | Completed | University of North Carolina, Chapel Hill | 13 | 2009-07-01 | 2011-05-13 |
| GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir Darunavir, Etravirine, Ritonavir - Healthy Volunteer | Phase 1 | Completed | ViiV Healthcare | 17 | 2009-04-01 | 2012-02-22 |
| Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study Etravirine - Endothelial Function, Lipids | Phase 1 | Completed | Indiana University | 28 | 2009-04-01 | 2011-01-07 |
| TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy. TMC125 - HIV, Pharmacokinetics | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 22 | 2009-03-01 | 2011-06-09 |
| TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers. Etravirine; Lopinavir; Ritonavir - HIV | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 16 | 2008-09-01 | 2011-06-09 |
| TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. TMC125 - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 18 | 2008-09-01 | 2011-06-09 |
HIV Infections (7) · Acquired Immunodeficiency Syndrome (5) · Infections (2) · Inflammation (1) · Insulin Resistance (1) · Mycoses (1)
Tibotec Pharmaceuticals, Ireland (4) · ViiV Healthcare (3) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · GlaxoSmithKline (1) · Indiana University (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen Research & Development, LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of North Carolina, Chapel Hill (1)
United States (6) · Belgium (1) · Brazil (1) · South Africa (1) · Spain (1)
Angela DM Kashuba, PharmD (1) · Kristine B Patterson, MD (1) · Richard Rutstein, MD (1) · Samir K Gupta, MD, MS (1)
PMID 23400742, PMID 23441978, PMID 35315687
2019 (1)